Recent advances in the pharmacotherapy for hyperbilirubinaemia in the neonate

Bibliography

• CHRISTENSEN T, AMUNDSEN I,KINN G, KJELDSTAD B: Terapienheter og belysningsforhold ved lysbehandling av nyfeidte med hyperbilirubinemi. SIS-Rapport No.2. National Institute of Radiation Hygiene, Osterds, Norway (1992).
   Google Scholar
• •A group from the Norwegian National Institute of Radiation Hygiene studied phototherapy units in nine Norwegian hospitals. Large differences were found between different hospitals and between single units within the same hospital. Irradiance values varied with a factor of 10.
   Google Scholar
• MAISELS MI P. hototherapy. In: Neonatal jaundice. Maisels MJ, Watchko JF (Eds), Harwood Academic Publishers, London, UK (2000):177–203.
   Google Scholar
• HANSEN TWR: Fetal and neonatal bilirubin metabolism. In: Neonataljaundice. Maisels MJ, Watchko JF (Eds), Harwood Academic Publishers, London, UK (2000):3–20.
   Google Scholar
• SCHMORL C: Zur Kenntnis des Ikterus neonatorum, insbesondere der dabei auftretenden Gehirnveränderungen. Verb. Dtsch. Pathol Ges. (1904) 6:109–115.
   Google Scholar
• •Schmorl examined the brains of 120 infants who had been jaundiced at the time of death. In 114 of 120 cases, the brain was diffusely yellow, while in the remaining six cases, he found spots of more intense yellow colouring in the basal ganglia and medulla oblongata. He coined the term kernicterus (German for jaundice of the nuclei) to describe this finding.
   Google Scholar
• ARKWRIGHT JA: A family series of fatal and dangerous cases of icterus neonatorum - fourteen cases in one family, with four survivors. Edinb. Med. J. (1902) 2:156–158.
   Google Scholar
• BERAUD LS: Observation sur fictere congenital. Jean Martel, Montpellier, France (1817).
   Google Scholar
• HERVIEUX JFE: De l'ictere des nouveau-nés. These, Paris, France (1847).
   Google Scholar
• HANSEN TWR, PAULSEN BS: Treatment of neonatal jaundice in 18th and 19th Century Europe. Pediatr. Res. (2003) 53:304A.
   Google Scholar
• WALLERSTEIN H: Treatment of severeerythroblastosis by simultaneous removal and replacement of the blood of thenewborn infant. Science (1946)19.103:583–584.
   Google Scholar
• DIAMOND LK: Erythroblastosis foetalis or haemolytic disease of the newborn. Proc. Royal. Soc. Med. (1947) 40:546–559.
   PubMedGoogle Scholar
• DIAMOND LK, ALLEN FH,20.THOMAS WO: Erythroblastosis fetalis.VII. Treatment with exchange transfusion. N Engl. J. Med. (1951) 244:39–49.
   Google Scholar
• HSIA DY, ALLEN F, GELLIS SS,DIAMOND LK: Erythroblastosis fetalis.21.VIII. Prevention of kernicterus. N Engl. .1. Med. (1952) 246:668–671.
   Google Scholar
• MOLLISON PL, CUTBUSH M:22.Haemolytic disease of the newborn. In: Recent advances M pediatrics. Gairdner D (Ed.), P Blakiston and Son, New York, NY, USA (1954):110.
   Google Scholar
• WATCHKOJF, OSKI F: Bilirubin 20mg/d1 = Vigintifobia. Pediatrics (1983) 71:660–663.
   PubMedGoogle Scholar
• HANSEN TWR: Therapeutic practices inneonatal jaundice: an international survey. Clin. Pediatr. (1996) 35:309–316.
   PubMedGoogle Scholar
• •In this survey of treatment guidelines in 108 NICUs across the world, significant disparity was documented as far as intervention limits. For example, the intervention limits for phototherapy in a 1-day-old term infant varied from 100 to 340 µM/1, whereas the indication for exchange transfusion at the same point in time ranged 170–425 µM/1.
   Google Scholar
• CREMER RJ, PERRYMAN PW, RICHARDS DH: Influence of light on the hyperbilirubinaemia of infants. Lancet (1958) 1:1094–1097.
   PubMed Web of Science ®Google Scholar
• •This is the first description of the effect of light on jaundiced newborns.
   Google Scholar
• OBES-POLLERI J, HILL WS:La fototerapia en las ictericias del recien nacido. Rev ChM Ped. (1964) 25:638.
   Google Scholar
• LUCEY JF, FERREIRO M, HEWITT J: Prevention of hyperbilirubinemia of prematurity by phototherapy. Pediatrics (1968) 40:1047–1054.
   Google Scholar
• VREMAN HJ, WONG RJ,STEVENSON DK et al.: Light-emitting diodes: a novel light source for phototherapy. Pediatr. Res. (1998) 44(5)804–809.
   Google Scholar
• DE CARVALHO M, DE CARVALHO D, TRZMIELINA S, LOPES JMA, HANSEN TWR: Intensified phototherapy using daylight fluorescent lamps. Acta Paediatr. (1999) 88:768–771.
   PubMed Web of Science ®Google Scholar
• MAISELS MJ, KRING E: Length of stay, jaundice, and hospital readmission. Pediatrics (1998) 101(6):995–998.
   PubMed Web of Science ®Google Scholar
• BROWN AK, JOHNSON L: Loss of concern about jaundice and the re-emergence of kernicterus in full term infants in the era of managed care. In: Yearbook of Neonatal and Perinatal Medicine. Fanaroff A, Klaus M (Eds), Mosby Yearbook, St. Louis, MO, USA (1996):17–28.
   Google Scholar
• EBBESEN F: Recurrence of kernicterus in term and near term infants in Denmark. Acta Paediatr. (2001) 89:1213–1217.
   Google Scholar
• •Ebbesen describes six cases of kernicterus in Denmark occurring within the period 1994–1998, while a search of national data could not find any cases having occurred during the previous 20 years. The author ascribes this epidemic to decreased concern and lessened vigilance as far as jaundice in neonates is concerned.
   Google Scholar
• HANSEN TWR: Kernicterus: an international perspective. Semin. Neonatol (2002) 7:103–109.
   PubMedGoogle Scholar
• HANSEN TWR: Kernicterus in term and near-term infants - the specter walks again. Acta Paediatr. (2000) 89:1155–1157.
   PubMedGoogle Scholar
• MAISELS MJ, NEWMAN TB: Bilirubin and neurological dysfunction-do we need to change what we are doing? Pediatr. Res. (2001) 50(6):677–678.
   Google Scholar
• DENNERY PA: Pharmaceutical interventions for the treatment of neonatal jaundice. Semin. Neonatol (2002) 7:111–119.
   PubMedGoogle Scholar
• ••This is an excellent and comprehensivereview of drug treatment for neonatal jaundice.
   Google Scholar
• VREMAN HJ, WONG RJ, STEVENSON DK: Alternative metalloporphyrins for the treatment of neonatal jaundice. " Perinatol 21:S108–S113.
   Google Scholar
• •The group from Stanford University have made many important contributions to the study of metalloporphyrins. (Also see [29, 37, 401).
   Google Scholar
• VREMAN HJ, EKSTRAND BC, STEVENSON DK: Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity. Pediatr. Res. (1993) 33:195–200.
   PubMed Web of Science ®Google Scholar
• QUATO MK, MAINES MD: Prevention of neonatal hyperbilirubinaemia in non-human primates by Zn-protoporphyrin. Biochem. J. (1985) 226:51–57.
   PubMedGoogle Scholar
• KAPPAS A, DRUMMOND GS, HENSCHKE C, VALAES T: Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics (1995) 95(4):468–474.
   PubMedGoogle Scholar
• ••Kappas and Drummond from RockefellerUniversity have done some of the seminal work on metalloporphyrins starting more than two decades ago, including important clinical studies of tin-mesoporphyrin in collaboration with Valaes. (Also see [33–36,41,43,51,52]).
   Google Scholar
• MARTINEZ JC, GARCIA HO, OTHEGUY LE, DRUMMOND GS, KAPPAS A: Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Pediatrics (1999) 103(1):1–5.
   PubMedGoogle Scholar
• VALAES T, PETMEZAKI S, HENSCHKE C, DRUMMOND GS, KAPPAS A: Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics (1994) 93(1):1–11.
   PubMed Web of Science ®Google Scholar
• VALAES T, DRUMMOND GS, KAPPAS A: Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns using an inhibitor of bilirubin production, Sn-mesoporphyrin. Pediatrics (1998) 101(5):E1.
   PubMedGoogle Scholar
• KAPPAS A, DRUMMOND GS, VALAES T: A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns. Pediatrics (2001) 108(1):25–30.
   PubMedGoogle Scholar
• KAPPAS A, DRUMMOND GS, MUNSON DP, MARSHALL JR: Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah's Witness newborns as an alternative to exchange transfusion. Pediatrics (2001) 108(6):1374–1377.
   PubMedGoogle Scholar
• HINTZ SR, VREMAN HJ, STEVENSON DK: Mortality of metalloporphyrin-treated neonatal rats after light exposure. Dev. Pharmacol Titer. (1990) 14(3):187–192.
   PubMedGoogle Scholar
• KEINO H, NAGAE H, MIMURA S, WATANABE K, KASHIWAMATA S: Dangerous effects of tin-protoporphyrin plus photoirradiation on neonatal rats. Eur. Pediatr. (1990) 149(4):278–279.
   PubMedGoogle Scholar
• CABLE E, GILDEMEISTER OS, PEPE JA, LAMBRECHT RW, BONKOVSKY HL: Mechanism of induction of heme oxygenase by metalloporphyrins in primary chick embryo liver cells: evidence against a stress-mediated response. Molec. Cell. Bioche. (1997) 169(1-2):13–20.
   PubMedGoogle Scholar
• YANG G, NGUYEN X, OU J, REKULAPELLI P, STEVENSON DK, DENNERY PA: Unique effects of zinc protoporphyrin on HO-1 induction and apoptosis. Blood (2001) 97(5):1306–1313.
   PubMedGoogle Scholar
• GALBRAITH RA, DRUMMOND GS, KAPPAS A: Suppression of bilirubin production in the Crigler-Najjar Type I syndrome: studies with the heme oxygenase inhibitor tin-mesoporphyrin.Pediatrics (1992) 89(2):175–182.
   PubMedGoogle Scholar
• RUBALTELLI FF, DARIO C, ZANCAN L: Congenital nonobstructive, nonhemolytic jaundice: effect of tin-mesoporphyrin. Pediatrics (1995) 95(6):942–944.
   PubMedGoogle Scholar
• KAPPAS A, DRUMMOND GS, GALBRAITH RA: Prolonged clinical use ofa heme oxygenase inhibitor: hematologicalevidence for an inducible but reversibleiron-deficiency state. Pediatrics (1993) 91(3):537–539.
   PubMedGoogle Scholar
• WIEDEMANN M, KONTUSH A, FINCKH B, HELLWEGE HH, KOHLSCHATTER A: Neonatal blood plasma is less susceptible to oxidation than adult plasma owing to its higher content of bilirubin and lower content of oxidizable fatty acids. Pediatr. Res. (2003) 53(5):843–849.
   PubMed Web of Science ®Google Scholar
• KITAMURA Y, ISHIDA Y, TAKATA K et al.: Hyperbilirubinemia protects against focal ischemia in rats.' NeuroscL Res. (2003) 71(4):544–550.
   PubMedGoogle Scholar
• DORE S, GOTO S, SAMPEI K et al.: Heme oxygenase-2 acts to prevent neuronal death in brain cultures and following transient cerebral ischemia.Neuroscience (2000) 99(4):587–592.
   PubMedGoogle Scholar
• CHANG EF, WONG RJ, VREMAN HJ et al.: Heme oxygenase-2 protects against lipid peroxidation-mediated cell loss and impaired motor recovery after traumatic brain injury. J. Neurosci. (2003) 23(9):3689–3696.
   PubMedGoogle Scholar
• STEINER AA, RESTE G, BRANCO LG: Role of the brain heme oxygenase-carbon monoxide pathway in stress fever in rats. Neurosci. Lett. (2003) 341(3):193–196.
   PubMedGoogle Scholar
• FIUMANA E, PARFENOVA H, JAGGER JH, LEFFLER CW: Carbon monoxide mediates vasodilator effects of glutamate in isolated pressurized cerebral arterioles of newborn pigs. Jim. Physiol Heart. Circ. Physiol (2003) 284(4):H1073–1079.
   Google Scholar
• NY L, ANDERSSON KE, GRUNDEMAR L: Inhibition by zinc protoporphyrin-IX of receptor-mediated relaxation of the rat aorta in a manner distinct from inhibition of haem oxygenase. Br. J. Pharmacol (1995) 115(1):186–190.
   PubMedGoogle Scholar
• DRUMMOND GS, KAPPAS A: Sn-protoporphyrin inhibition of fetal and neonatal brain heme oxygenase. Transplacental passage of the metalloporphyrin and prenatal suppression of hyperbilirubinemia in the newborn animal. Clin. Invest. (1986) 77:971–976.
   Google Scholar
• KAPPAS A, DRUMMOND GS, MANOLA T, PETMEZAKI S, VALAES T: Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics (1988) 81:485-497. 1946Expert Op/n. Pharmacother. (2003) 4(11)
   Google Scholar
• JUCKETT M, ZHENG Y, YUAN H et al: Heme and the endothelium. Effects of nitric oxide on catalytic iron and heme degradation by heme oxygenase. Biol. Chem. (1998) 273(36):23388–23397.
   Google Scholar
• OROSZLAN G, LAKATOS L, SZABO L, MATKOVICS B, KARMAZSIN L: Heme oxygenase activity is decreased by D-penicillamine in neonates.Experientia (1983) 39(8):888–889.
   PubMedGoogle Scholar
• LAKATOS L, KOVER B, OROSZLAN G, VEKERDY Z: D-penicillamine therapy in ABO hemolytic disease of the newborn infant. Eur. Pediatr. (1976) 123(2):133–137.
   PubMedGoogle Scholar
• PECES R, RIERA JR, ARBOLEYA LR, LOPEZ-LARREA C, ALVAREZ J:Goodpasture's syndrome in a patient receiving penicillamine and carbimazole.Nephron (1987) 45(4):316–320.
   Google Scholar
• LOUIE S, GAMBLE CN, CROSS CE: Penicillamine associated pulmonary hemorrhage. J. Rheumatol (1986) 13(5):963–966.
   PubMedGoogle Scholar
• NARAYANAN CS, BEHARI M: Generalized myasthenia gravis following use of D-penicillamine in Wilson's disease.J. Assoc. Phys. India (1999) 47(6):648.
   Google Scholar
• KAUFMAN DW, KELLY JP,JURGELON JM et al.: Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eut: Haematol Sapp]. (1996) 60:23–30.
   Google Scholar
• FISHEL B, TISHLER M, CASPI D, YARON M: Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis.Ann. Rheum. Dis. (1989) 48(7):609–610.
   Google Scholar
• SATO K, HARA T, KONDO T, IWAO H, HONDA S, UEDA K: High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility.Acta Paediam. Scand. (1991) 80:163–166.
   PubMedGoogle Scholar
• ••This appears to have been the first todescribe the therapeutic effect of intravenous immunoglobulin, while the study by [62] extended this observation to a larger group of patients.
   Google Scholar
• ROBO J, ALBRECHT K, LASCH P et al.: High-dose intravenous immune globulin therapy for hyperbilirubinemia cause by Rh hemolytic disease. .I. Pediatr. (1992) 121:93–97.
   Google Scholar
• ALCOCK GS, LILEY H: Immunoglobulininfusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst. Rev.v(2002) 3:CD003313.
   Google Scholar
• GOTTSTEIN R, COOKE RW: Systematicreview of intravenous immunoglobulin in haemolytic disease of the newborn.Arch. Dis. Child. Fetal. Neonatal. Ed. (2003) 88:F6–F10.
   Google Scholar
• HAMMERMAN C, VREMAN HJ, KAPLAN M, STEVENSON DK:Intravenous immune globulin in neonatal immune hemolytic disease: does it reduce hemolysis? Acta Pediatr. (1996) 85(11):1351–1353.
   Google Scholar
• LAVIN A, SUNG C, KLIBANOV AM, LANGER R: Enzymatic removal of bilirubin from blood: a potential treatment for neonatal jaundice. Science (1985) 230(4725):543–545.
   PubMed Web of Science ®Google Scholar
• HANSEN TWR: Acute management of extreme neonatal jaundice - the potential benefits of intensified phototherapy and interruption of enterohepatic bilirubin circulation. Acta Paediam. (1997) 86:843–846.
   PubMedGoogle Scholar
• ODELL GB, GUTCHER GR, WHITINGTON PF, YANG G: Enteral administration of agar as an effective adjunct to phototherapy of neonatal hyperbilirubinemia. Pediatr. Res. (1983) 17(10):810–814.
   PubMed Web of Science ®Google Scholar
• CAGLAYAN S, CANDEMIR H, AKSIT S,KANSOY S, ASIK S, YAPRAK I: Superiority of oral agar and phototherapy combination in the treatment of neonatal hyperbilirubinemia. Pediatrics (1993) 92(1):86–89.
   PubMed Web of Science ®Google Scholar
• ROMAGNOLI C, POLIDORI G, FOSCHINI M et al.: Agar in the management of hyperbilirubinaemia in the premature baby. Arch. Dis. Child (1975) 50(3):202–204.
   PubMed Web of Science ®Google Scholar
• WINDORFER A JR, KUNZER W, BOLZE H, ASCHER K, WILCKEN F, HOEHNE K: Studies on the effect of orally administered agar on the serum bilirubin level of premature infants and mature newborns. Acta Paediatr. Scand. (1975) 64(5):699–702.
   PubMedGoogle Scholar
• MELONI T, COSTA S, CORTI R, CUTILLO S: Agar in control of hyperbilirubinemia of full-term newborn infants with erythrocyte G-6-PD deficiency. Biol. Neonate (1978) 34(5-6):295–298.
   PubMedGoogle Scholar
• DAVIS DR, YEARY RA, LEE K: Activated charcoal decreases plasma bilirubin levels in the hyperbilirubinemic rat. Pediatr. Res. (1983) 17(3):208–209.
   PubMedGoogle Scholar
• KIMURA M, MATSUMURA Y, KONNO T, MIYAUCHI Y, MAEDA H: Enzymatic removal of bilirubin toxicity bybilirubin oxidase in vitro and excretion of degradation products in vivo. Proc. Soc. Exp. Biol. Med. (1990) 195(1):64–69.
   PubMedGoogle Scholar
• JOHNSON L, DWORANCZYK R, ABBASI M, DALIN C: Bilirubin wddase feedings significantly decrease serum bilirubin levels in jaundiced infant Gunn rats. Pediatr. Res. (1988) 23:412A.
   Google Scholar
• HAFKAMP AM, HAVINGA R, SINAASAPPEL M, ELFERINK RPJO, VERKADE HJ: Highly effective enteral treatment of unconjugated hyperbilirubinemia in Gunn rats.Pediatr. Res. (2003) 53:400A.
   Google Scholar
• GOURLEY G: Breast-feeding, neonatal jaundice and kernicterus. Semin. Neonatol (2002) 7:135–141
   PubMedGoogle Scholar
• GOURLEY G, KREAMER B,COHNEN M, KOSOROK MR: Neonataljaundice and diet. Arch. Pediatr. Adolesc. Med. (1999) 153:184–188
   PubMedGoogle Scholar
• OKUDA H, POTTER BJ, BLADES B, MCHUGH TA, JACOBS LN, BERK PD:Dose-related effects of phenobarbital on hepatic glutathione-S-transferase activity and ligandin levels in the rat. Drug. Metab. Dispos. (1989) 17(6):677–682.
   PubMedGoogle Scholar
• STERN L, KHANNA NN, LEVY G, YAFFE SJ: Effect of phenobarbital on hyperbilirubinemia and glucuronide formation in newborns. Am. I Dis. Child (1970) 120(1):26–31.
   PubMedGoogle Scholar
• VALAES T, KIPOUROS K,PETMEZAKI S, SOLMAN M,DOXIADIS SA: Effectiveness and safety of prenatal phenobarbital for the prevention of neonatal jaundice. Pediatr. Res. (1980) 14(8):947–952.
   PubMedGoogle Scholar
• ARIAS IM: Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults. J. Clin. Invest. (192) 41:2233-2245.
   Google Scholar
• HANSEN TWR, TOMMARELLO S: Effects of phenobarbital on bilirubin clearance and metabolism in rat brain.Biol. Neonate. (1998) 73:106–111.
   PubMedGoogle Scholar
• FARWELL JR, LEE YJ, HIRTZ DG, SULZBACHER SI, ELLENBERG JH, NELSON KB: Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. N Engl. J. Med. (1990) 322 (6):364–369.
   PubMed Web of Science ®Google Scholar
• LINDENBAUM A, HERNANDORENA X, VIAL M et al.: Clofibrate for the treatment of hyperbilirubinemia in neonates born at term: a double blind controlled study. Arch. Franc Pediatric.. (1981) 38\(Suppl. 1):867–873.
   Google Scholar
• TIRIBELLI C, OSTROW JD: New concepts in bilirubin chemistry, transport and metabolism: report of the second international bilirubin workshop, April 9-11, 1992, Trieste, Italy. Hepatology (1993) 17:715–736.
   PubMedGoogle Scholar
• KAPITULNIKJ, GONZALEZ FJ: Marked endogenous activation of the CYP 1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Ma Pbarmacol. (1993) 43:722–725.
   Google Scholar
• DE MATTEIS F, DAWSON SJ, PONS N, PIPINO S: Bilirubin and uroporphyrinogen oxidation by induced cytochrome P4501A and cytochrome P4502B. Role of polyhalogenated biphenyls of different configuration. Biochent. Pbarmacol. (2002) 63:615–624.
   Google Scholar
• HANSEN TWR: Bilirubin oxidation inbrain. Molec. Genet. Metab. (2000) 71:411–417.
   PubMedGoogle Scholar
• JORRITSMA U, SCHRADER E, KLAUNICK G et al: Monitoring of cytochrome P450 IA activity by determination of the urinary pattern of caffeine metabolites in Wistar and hyperbilirubinemic Gunn rats. Toxicology (2000) 144:229–236.
   PubMedGoogle Scholar
• SURESH G, LUCEY JF: Lack of deafness in Crigler-Najjar syndrome Type 1: a patient survey. Pediatrics (1997) 100:e9.
   Web of Science ®Google Scholar
• HUANG W, ZHANG J, CHUA SS et al.: Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. USA (2003) 100(7):4156–4161.
   PubMed Web of Science ®Google Scholar
• LI YQ, PRENTICE DA, HOWARD ML, MASHFORD ML, DESMOND PV: Bilirubin and bile acids may modulate their own metabolism via regulating uridine diphosphate-glucuronosyltransferase expression in the rat. Gastroenterol Hepatol (2000) 15(8):865–870.
   Google Scholar
• TZAMELI I, PISSIOS P, SCHUETZ EG, MOORE DD: The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Molec. Cell. Biol. (2000) 20(9):2951–2958.
   PubMed Web of Science ®Google Scholar
• ODELL GB, CUKIER JO, SEUNGDAMRONG S, ODELL JL: The displacement of bilirubin from albumin. Binh Defects Orig. Artie. Ser. (1976) 12:192–200.
   PubMedGoogle Scholar
• BRATLID D: The effect of antimicrobial agents on bilirubin binding by human erythrocytes. Scand. I Clin. Lab. Invest. (1972) 30:331–337.
   Google Scholar
• BRATLID D: Pharmacologic aspects of neonatal hyperbilirubinemia. Birth Defects Orig. Artie. Ser. (1976) 12:184–189.
   PubMedGoogle Scholar
• SILVERMAN WA, ANDERSEN DH, BLANC WA et al: A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics (1956) 18:614–624.
   PubMed Web of Science ®Google Scholar
• •This publication was seminal in the discovery of the importance of bilirubin binding to albumin and the impact of displacement by drugs or endogenous compounds.
   Google Scholar
• COOPER-PEEL C, BRODERSEN R, ROBERTSON A: Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Pbannacol Toxicol (1996) 79:297-299.loo. HANSEN TWR: Ibuprofen for closure of patent ductus arteriosus - is it really safe in hyperbilirubinemic infants? Eur. Pediatr. (2003) 162:356.
   Google Scholar
• WATCHKO JF, DAOOD MJ,HANSEN TWR: Brain bilirubin content is increased in P-glycoprotein deficient transgenic null mutant mice. Pediatr. Res. (1998) 44:763–766.
   PubMed Web of Science ®Google Scholar
• •This was the first publication showing that specific barrier properties of the blood-brain barrier may be of importance for bilirubin access to the brain.
   Google Scholar
• FORD JM, HAIT WN: Pharmacological circumvention of multidrug resistance. Cytotechnology (1993) 12:171–212.
   PubMed Web of Science ®Google Scholar
• CARLSEN SA, TILL JE, LING V: Modulation of membrane drug permeability in Chinese hamster ovary cells. Biotblin. Biophys. Acta. (1976) 455:900–912.
   PubMed Web of Science ®Google Scholar
• FARDEL 0, LECUREUR V, LOYER P, GUILLOUZO A: Rifampin enhances anticancer drug accumulation and activity in multidrug-resistant cells. Biochent. Pbannacol (1995) 49:1255–1260.
   PubMed Web of Science ®Google Scholar
• HANK(?) E, TOMMARELLO S, WATCHKO JF, HANSEN TWR: Pharmacological inhibition of blood-brain barrier P-glycoprotein increases brain bilirubin and alters regional distribution of bilirubin in rat brain. Pediatr. Res. (2003) 54(4):441–445.
   Google Scholar
• •In an editorial comment to this paper, Hascoet J-M writes: The article by Hanko et al. in this issue introduces a new concept in the distribution of bilirubin. This concept might be a new clue in theunderstanding of bilirubin toxicity and its variability'.
   Google Scholar
• MACDONALD MG: Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency. Pediatrics (1995) 96:734–738.
   PubMed Web of Science ®Google Scholar
• JOHNSON LH, BHUTANI VK, BROWN AK: System-based approach to management of neonatal jaundice and prevention of kernicterus. Pediatr. (2002) 140:396-403.Ha JOSEPH R, HO LY, GOMEZ JM, RAJDURAI VS, SIVASANKARAN S, YIP YY: Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore. SE. Asian. I Bop. Med. Publ. Health. (1999) 30\(Suppl. 2):70–71.
   Google Scholar
• LI KC, LAI SS, LAM ST: Adequacy and pitfalls of G6PD deficiency counseling in Hong Kong. SEAsianj Bop. Med. Publ. Health. (1999) 30\(Suppl. 2):79–83.llo. BHUTANI VK, JOHNSON L, SIVIERI EM: Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics (1999) 103:6–14.
   Google Scholar
• •This publication describes the possibilities, as well as the limitations of our current tools for predicting neonatal jaundice.
   Google Scholar
• BHUTANI VK, GOURLEY GR, ADLER S et al.: Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics (2000) 106:e17.
   PubMed Web of Science ®Google Scholar
• •This publication describes the possibilities, as well as the limitations of our current tools for predicting neonatal jaundice.
   Google Scholar
• STEVENSON DK, FANAROFF AA, MAISELS MJ et al: Prediction of hyperbilirubinemia in near-term and term infants. Perinatol (2001) 21:S63–S72.
   Google Scholar
• •This publication describes the possibilities, as well as the limitations of our current tools for predicting neonatal jaundice.Affiliation 1948Expert Op/n. Pharmacother. (2003) 4(11)
   Google Scholar